← All trials
NCT04329520
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2020
- Primary completion
- Jun 30, 2020
- Completion date
- Jul 31, 2020
- First posted
- Apr 1, 2020
- Last posted
- Apr 1, 2020
- Enrollment
- 4000
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Effice Servicios Para la Investigacion S.L.Lead sponsor
- Government of SpainStudy director
- Government of SpainCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.